India Pharma Outlook Team | Saturday, 24 May 2025
Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies has reported a standalone net profit of Rs. 82.44 crore for the FY25 ended March 2025 as against net profit of Rs. 93.37 crore FY24. Total Income from operations for the FY25 was reported at Rs. 645.71 crore over previous fiscal’s same period revenue from operations of Rs. 614.97 crore. Company reported EBITDA of Rs. 123.97 in FY25 as compared to Rs. 134.33 crore EBITDA in the corresponding period last year. EPS for FY25 was at Rs. 41.11 per share. Company has recommended a dividend of 18 percent, Rs. 1.80 per share on the face value of Rs. 10 per share for the FY 2024-25.
The company reported a profit before tax of Rs. 109.19 crores for the year ended in March 2025 as compared to Rs. 122.24 crores in FY23-24. Foreign Institutional Investors (FIIs) have steadily increased their stake in the company, rising from 3.93 percent in March 2024 to 5% as on 31st March 2025. With a clear growth strategy, the company is targeting revenue of Rs. 750 crores by FY26, driven by business expansion into high-value product lines and entry into new markets.
Commenting on the Q4 and FY25 performance, Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “Lincoln Pharmaceuticals has delivered consistent profit growth from FY13 through FY24 - a testament to our sound business fundamentals and execution capabilities. Company remains committed to net debt-free and continues to leverage strategic product launches in both domestic and international markets to strengthen our market presence. We are committed to significantly improve our growth going forward. With a clear focus on operational excellence and geographic expansion, we are well-positioned to achieve our Rs. 750 crore revenue target by FY26.” Highlights: - Q4 FY25 Results
For the Quarter ended in March 2025, company reported a standalone net profit of Rs. 11.62 crore, EBITDA of Rs. 19.84 crore and Total Income from operations at Rs. 161.30 crore. EPS for Q4FY25 was at Rs. 5.78 per share.
The company’s growth strategy focuses on expanding its global footprint by registering new products for export, enhancing market presence, and utilizing state-of-the-art manufacturing facilities that meet international standards. With a strong foundation in the acute segment, the company is now building a robust portfolio in lifestyle and chronic segments, particularly in women’s healthcare and dermatology. Supported by healthy cash accruals, no-term debt, and strong return ratios, the company’s liquidity remains solid. Committed to R&D and innovation, it boasts a portfolio of over 1,700 registered products and 700 more in development.
Currently exporting to 60+ countries across East and West Africa, Central and North America, Latin America, and Southeast Asia, the company recently entered the Canadian market after Australia’s TGA and the European Union’s GMP Approvals. These milestones, along with product registration for its Cephalosporin plant in Mehsana, are key drivers of its global expansion strategy to over 90 plus countries. Aligned with these efforts, the company remains on track to achieve its ambitious Rs. 750 crore revenue target by FY26.
Also Read: Alembic Gets USFDA Approval for generic high blood pressure treatment drug
Company has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; ISO-9001:2015, ISO-14001:2015 and ISO-45001:2018. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filed 25 plus patent applications and is awarded with seven patents.
, CDSCO.jpg)
